News
IPSEY
46.70
NaN%
--
Weekly Report: what happened at IPSEY last week (0720-0724)?
Weekly Report · 1d ago
Ipsen phase 3 Bylvay trial in biliary atresia misses primary goal
Seeking Alpha · 4d ago
Weekly Report: what happened at IPSEY last week (0713-0717)?
Weekly Report · 07/20 10:04
Weekly Report: what happened at IPSEY last week (0706-0710)?
Weekly Report · 07/13 10:05
Here's Why Ipsen S.A. Just Paid €700M For Memo Therapeutics AG
Seeking Alpha · 07/10 12:40
Ipsen's Dysport Becomes First Botulinum Toxin To Show Statistically Significant Efficacy In Episodic Migraine, Positioning It As Potential First-In-Class Treatment
Benzinga · 07/09 06:58
Weekly Report: what happened at IPSEY last week (0629-0703)?
Weekly Report · 07/06 10:08
Ipsen to acquire Memo Therapeutics in deal worth over €700M
Seeking Alpha · 07/01 05:24
Weekly Report: what happened at IPSEY last week (0622-0626)?
Weekly Report · 06/29 10:04
Ipsen to buy Kartos Therapeutics for $450M to boost oncology pipeline
Seeking Alpha · 06/29 09:10
Weekly Report: what happened at IPSEY last week (0615-0619)?
Weekly Report · 06/22 10:12
Weekly Report: what happened at IPSEY last week (0608-0612)?
Weekly Report · 06/15 10:13
Weekly Report: what happened at IPSEY last week (0601-0605)?
Weekly Report · 06/08 10:09
Weekly Report: what happened at IPSEY last week (0525-0529)?
Weekly Report · 06/01 10:13
Weekly Report: what happened at IPSEY last week (0518-0522)?
Weekly Report · 05/25 10:16
Weekly Report: what happened at IPSEY last week (0511-0515)?
Weekly Report · 05/18 10:16
Ipsen : Corabotase Data Demonstrate Rapid, Durable Efficacy In Glabellar Lines
NASDAQ · 05/16 14:11
Weekly Report: what happened at IPSEY last week (0504-0508)?
Weekly Report · 05/11 10:13
Weekly Report: what happened at IPSEY last week (0427-0501)?
Weekly Report · 05/04 10:11
Weekly Report: what happened at IPSEY last week (0420-0424)?
Weekly Report · 04/27 10:13
More
Webull provides a variety of real-time IPSEY stock news. You can receive the latest news about Ipsen Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPSEY
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.